MARTEK BIOSCIENCES CORP
MATK
MATK was delisted on the 25th of February, 2011.
0 hedge funds and large institutions have $0 invested in MARTEK BIOSCIENCES CORP in 2016 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $133K → $0 (-$133K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBL
Sargent Bickham Lagudis
Boulder,
Colorado
|
-$133K |
MATK Hedge Fund Activity: Q3 2016 in Review
0 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in MARTEK BIOSCIENCES CORP (MATK) for Q3 2016, worth a combined $0 — down 100% from $133K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of MATK and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Sargent Bickham Lagudis, exiting entirely with an estimated $133K sold.
- 0 institutional investors held MARTEK BIOSCIENCES CORP (MATK) as of Q3 2016, down from 1 in Q2 2016.
- Funds reported $0 of MARTEK BIOSCIENCES CORP stock for Q3 2016, down 100% quarter-over-quarter.
- 0 funds opened new MARTEK BIOSCIENCES CORP positions in Q3 2016 and 1 closed out, a net change of -1 holder.
- The largest MARTEK BIOSCIENCES CORP seller in Q3 2016 was Sargent Bickham Lagudis, an estimated $133K sold.
Based on aggregated 13F filings for Q3 2016.